Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

4(80.0%)

Phase 1

1(20.0%)

5Total

Phase 2(4)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05737199Phase 2Active Not Recruiting

Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma

Role: lead

NCT06992284Enrolling By Invitation

A Prognostic Study for Patients With Cardiovascular Disease in Niigata

Role: lead

NCT00764595Phase 2Completed

Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor

Role: collaborator

NCT00769782Phase 2Completed

Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor

Role: collaborator

NCT02835742Phase 2Completed

Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan

Role: lead

NCT02840708Phase 1Completed

SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study

Role: lead

All 6 trials loaded